Agile Therapeutics, Inc.
AGRX
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 16.78% | 61.84% | 43.08% | 66.04% | 63.25% |
| Total Depreciation and Amortization | -25.51% | -61.89% | -74.84% | -81.32% | -76.56% |
| Total Amortization of Deferred Charges | -65.19% | -52.02% | -46.01% | -42.38% | -28.48% |
| Total Other Non-Cash Items | 157.68% | 44.86% | 65.43% | 2.86% | -49.19% |
| Change in Net Operating Assets | 293.70% | -60.26% | 393.16% | 251.66% | -301.95% |
| Cash from Operations | 93.99% | 54.11% | 73.36% | 77.83% | 46.34% |
| Capital Expenditure | -- | -- | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 100.00% | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 79.23% | 76.48% | 92.25% | 93.68% | -157.72% |
| Issuance of Common Stock | -85.66% | -67.83% | -76.76% | -83.60% | -13.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.24% | -63.19% | -68.95% | -81.14% | -48.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.62% | -364.29% | 80.65% | 61.91% | 21.76% |
